McNerney KO, Moskop A, Winestone LE, Baggott C, Talano JA, Schiff D, Rossoff J, Modi A, Verneris MR, Laetsch TW, Schultz L. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 Jan;30(1):75.e1-75.e11. doi: 10.1016/j.jtct.2023.10.004. Epub 2023 Oct 8. PMID: 37816472.

10.1016/j.jtct.2023.10.004

Jonathan D. Bender, Sudarshawn Damodharan, Christian M. Capitini, Amy Moskop, Keri Toner, Anant Vatsayan, Julie-An Talano, Christina Baggott, Deborah Schiff, Emmanuel Katsanis, Arunkumar J. Modi, Troy C. Quigg, Sunil S. Raikar, Liora M. Schultz, Lauren Pommert; Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood Adv 2024; 8 (15): 4164–4168. doi: https://doi.org/10.1182/bloodadvances.2024012928

10.1182/bloodadvances.2024012928

Kevin McNerney et al., High disease burden and severe neutropenia predict HLH toxicities in patients with B-acute lymphoblastic leukemia (B-ALL) treated with tisagenlecleucel in the PRWCC, ASTCT 2023, Abstract

10.1016/S2666-6367(23)00331-7

Kevin McNerney et al., Clinical practice patterns and factors driving usage of consolidative HSCT post-tisagenlecleucel, ASTCT 2023, Abstract

10.1016/S2666-6367(23)00335-4

Maya Eylon et al., Mediport Use as an Acceptable Standard for CAR T Cell Infusion, ASTCT 2023, Abstract

10.1016/S2666-6367(23)00323-8

McNerney KO, Lim SS, Vatsayan A, Dreyzin A, Baggott C, Prabhu S, Pacenta H, Philips C, Rossoff J, Stefanski H, Talano JA, Moskop A, Margossian S, Verneris M, Myers D, Karras N, Brown P, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Baumeister S, Fabrizio V, Chinnabhandar V, Goksenin Y, Curran K, Mackall CL, Laetsch T, Schultz L. Chimeric Antigen Receptor (CAR)-associated Hemophagocytic Lymphohistiocytosis (HLH) with use of commercial Tisagenlecleucel in the Pediatric Real World CAR Consortium (PRWCC): Risk Factors and Outcomes, ASTCT 2022, Late-breaking Abstract

10.1016/S2666-6367(23)00323-8

Pacenta H, Schultz L, Baggot C, Shah N, Prabhu S, Phillips C, Rossoff J, Stefanski H, Talano JA, Moskop A, Margossian S, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Barsan V, Goksenin Y, Curran K, Mackall CL, Laetsch T. Real World Treatment of Pediatric Patients with Down Syndrome and Relapsed/Refractory B-ALL Treated with Tisagenlecleucel, SIOP 2021, Oral Abstract

​

Barsan V, Baggot C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stefanski H, Talano JA, Moskop A, Margossian S, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Chinnabhandar V, Kunicki M, Gokesnin Y, Curran K, Mackall CL, Laetsch T, Schultz L. Real World Indications for Chimeric Antigen Receptor T cell Therapy and Referral Patterns in Pediatric Patients with Relapsed of High-Risk Leukemia, SIOP, Abstract

​

Schultz L, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW. Predictive Value of Next-generation Sequencing (NGS) following Tisagenlecleucel in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia, ASTCT 2021, Abstract

10.1016/S2666-6367(21)00267-0

Moskop A, Talano JA, Verneris M, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stafanski H, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW, Schultz L. Immune Reconstitution and Infections in the Real-World use of Tisagenlecleucel in Pediatric and Young Adult Acute Lymphoblastic Leukemia, ASTCT 2021, Abstract

10.1016/S2666-6367(21)00431-0

Fabrizio VA, Phillips CL, Baggott C, Prabhu S, Pacenta H, Rossoff J, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW, Schultz L, Real-World Treatment of Pediatric Patients with Relapsed/Refractory CNS B-Cell Leukemia using Tisagenlecleucel, ASTCT 2021, Abstract

10.1016/S2666-6367(21)00431-0

Stefanski H, Eaton A, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW, Schultz L, Post-Relapse Outcomes Following Tisagenlecleucel: Poor Survival, Despite Current Salvage Therapies: Results from the Pediatric Real World CAR Consortium (PRWCC), ASTCT 2021, Oral Abstract

10.1016/S2666-6367(21)00152-4

Moskop A, Breese E, Gest E, Pommert L, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW, Schultz L, Real-World Use of Tisagenlecleucel in Infant Acute Lymphoblastic Leukemia, ASTCT 2021, Oral Abstract

10.1182/bloodadvances.2021006393

Stefanski H, Eaton A, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW, Schultz L, Impact of Tisagenlecleucel Dose on Relapse: Results from the Pediatric Real World Consortium, ASTCT 2021, Late-breaking Abstract

​

Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Mackall CL, Bhatia S, Curran KJ, Laetsch TW, Liora Schultz, Inferior Outcomes Among Black Childhood Acute Lymphoblastic Leukemia Patients Following Tisagenlecleucel ASTCT 2021, Late-breaking Abstract

​

Curran KJ, Fabrizio V, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Mackall CL, Laetsch TW, Schultz L, Fludarabine Pharmacokinetics on Outcomes Following Tisagenlecleucel in Pediatric Acute Lymphoblastic Leukemia, ISTCT 2021, Oral Abstract

​

Schultz L, Baggott C, Prabhu S, Pacenta H, Phillips C, Rossoff J, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW. Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel; Results from the Pediatric Real World CAR Consortium (PRWCC), ASH 2020, Oral Abstract

​

Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips C, Stafanski H, Talano JA, Moskop A, Margossian SP, Verneris M, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Wilcox R, Rabik C, Fabrizio V, Rouce R, Chinnabhandar V, Kunicki M, Goksenin Y, Curran KJ, Mackall CL, Laetsch TW, Schultz L. Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia using Tisagenlecleucel that is Out of Specification for Commercial Release, ASH 2020, Abstract

10.1182/blood-2020-136674

Anthony Ross et al., Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel, ASH 2020, Abstract

10.1182/blood-2022-163336

Vanessa Fabrizio et al., Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults, ASH 2020, Abstract

10.1182/blood-2022-169603

John Molina et al., Cytogenetics risk stratification in the pediatric CAR setting diverge from established predictive criteria used for chemotherapy, ASH 2020, Abstract

10.1182/blood-2022-165951

Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski MC, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023 Feb 28;7(4):541-548. doi: 10.1182/bloodadvances.2022007246. PMID: 35938863; PMCID: PMC9979765.

10.1182/bloodadvances.2022007246

McNerney KO, Lim SS, Ishikawa K., Dreyzin A, Vatsayan A, Chen J, Baggott C, Prabhu S, Pacenta HL, Philips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Verneris MR, Myers D, Karras NA, Brown PA, Bonifant CL, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Baumeister SH, Fabrizio VA, Chinnabdhander V, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz L. HLH-like toxicities predict poor survival following real-world use of tisagenlecleucel in children and young adults with B-ALL, Blood Advances March 1, 2023. https://doi.org/10.1182/bloodadvances.2022008893

10.1182/bloodadvances.2022008893

Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Baumeister S, Verneris MR, Myers GD, Karras NA, Cooper S, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Fabrizio V, Chinnabhandar V, Kunicki M, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023 Oct 26;65:102268. doi: 10.1016/j.eclinm.2023.102268. PMID: 37954907; PMCID: PMC10632672.

10.1016/j.eclinm.2023.102268

Eylon M, Prabhu S, John S, King MJM, Bhatt D, Curran KJ, Erickson C, Karras NA, Phillips CL, Satwani P, Hermiston M, Southworth E, Baumeister SHC, Talano JA, MacMillan ML, Rossoff J, Bonifant CL, Myers GD, Rouce RH, Toner K, Driscoll TA, Katsanis E, Salzberg DB, Schiff D, De Oliveira SN, Capitini CM, Pacenta HL, Pfeiffer T, Shah NC, Huynh V, Skiles JL, Fraint E, McNerney KO, Quigg TC, Krueger J, Ligon JA, Fabrizio VA, Baggott C, Laetsch TW, Schultz LM. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023 Oct 27;14:1239132. doi: 10.3389/fimmu.2023.1239132. PMID: 37965315; PMCID: PMC10642031.

10.3389/fimmu.2023.1239132

Christa Krupski et al., Outcomes following Tisagenlecleucel Reinfusion in Children and Young Adults with B-cell Acute Lymphocytic Leukemia, ASTCT 2023, Late-Breaking Oral Abstract

​

Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 Nov 25;138(21):2138-2142. doi: 10.1182/blood.2021012392. PMID: 34499715; PMCID: PMC8617436.

10.1182/blood.2021012392

Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 Jan 25;6(2):600-610. doi: 10.1182/bloodadvances.2021005564. PMID: 34794180; PMCID: PMC8791593.

10.1182/bloodadvances.2021005564

Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 Mar 20;40(9):945-955. doi: 10.1200/JCO.20.03585. Epub 2021 Dec 9. PMID: 34882493; PMCID: PMC9384925.

10.1200/JCO.20.03585

Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 Apr 12;6(7):1961-1968. doi: 10.1182/bloodadvances.2021006418. Erratum in: Blood Adv. 2023 Jun 27;7(12):2924. PMID: 34788386; PMCID: PMC9006295.

10.1182/bloodadvances.2021006418

Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 Jul 26;6(14):4251-4255. doi: 10.1182/bloodadvances.2021006393. PMID: 35580324; PMCID: PMC9327536.

10.1182/bloodadvances.2021006393

Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023 Jan 10;41(2):354-363. doi: 10.1200/JCO.22.01076. Epub 2022 Sep 15. PMID: 36108252; PMCID: PMC9839307.

10.1200/JCO.22.01076